Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
20 10 2020
20 10 2020
Historique:
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
11
11
2020
Statut:
ppublish
Résumé
The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse. To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries. Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening. World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics. Self-report of having ever had a screening test for cervical cancer. Of the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened. In this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening.
Identifiants
pubmed: 33079153
pii: 2771901
doi: 10.1001/jama.2020.16244
pmc: PMC7576410
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1532-1542Subventions
Organisme : NIA NIH HHS
ID : R01 AG034479
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI112339
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG041710
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009775
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236546
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007433
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG034263
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Psychooncology. 2017 Feb;26(2):161-172
pubmed: 27072589
World J Clin Oncol. 2015 Dec 10;6(6):281-90
pubmed: 26677441
Lancet Glob Health. 2018 Feb;6(2):e152-e168
pubmed: 29248365
PLoS One. 2012;7(11):e48834
pubmed: 23155413
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
Syst Rev. 2013 May 24;2:35
pubmed: 23706117
Lancet Glob Health. 2020 Jan;8(1):e39-e49
pubmed: 31837954
Indian J Cancer. 2018 Oct-Dec;55(4):318-326
pubmed: 30829264
Pan Afr Med J. 2015 Jul 30;21:231
pubmed: 26523173
Int J Gynecol Cancer. 2012 Jul;22(6):908-21
pubmed: 22672987
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:47-56
pubmed: 28691334
Glob Health Action. 2015 Jan 22;8:26282
pubmed: 25623612
Int J Gynaecol Obstet. 2018 Dec;143(3):267-276
pubmed: 30144050
BMJ. 2015 Jul 03;351:h3084
pubmed: 26142020
J Glob Oncol. 2016 Aug 17;3(4):400-408
pubmed: 28831448
Fam Pract. 2012 Aug;29(4):462-6
pubmed: 22090193
Arch Gynecol Obstet. 2012 Dec;286(6):1487-505
pubmed: 23011733
BMJ Open. 2017 Jul 19;7(7):e016309
pubmed: 28724543
Lancet. 2017 Nov 11;390(10108):2143-2159
pubmed: 28886907
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
BMC Womens Health. 2014 Mar 12;14(1):44
pubmed: 24618416
Lancet Glob Health. 2016 Jul;4(7):e453-63
pubmed: 27340003
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:33-40
pubmed: 28691330
Gynecol Oncol Rep. 2017 Mar 03;20:58-61
pubmed: 28337474
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593